ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Ethnopharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1539704
This article is part of the Research TopicCannabis and Cannabinoids for Pain Treatment: Clinical and Non-Clinical Advances on Mechanisms and ApplicationsView all 4 articles
Cannabis-Based Extract for Managing Pain in Dogs with Osteoarthritis: Efficacy and Safety Assessment
Provisionally accepted- 1Universidade Federal da Integração Latino Americana, Laboratório de Cannabis Medicinal e Ciência Psicodélica, Foz do Iguaçu, Brazil
- 2Popvet Hospital Veterinário, Foz do Iguaçu, Paraná, Brazil
- 3Santa Cannabis Association, Florianópolis, Brazil
- 4Universidade Federal da Integração Latino Americana, Environmental an Food Interdisciplinary Studies Laboratory, Foz do Iguaçu, Brazil
- 5Universidade Federal da Integração Latino-Americana, Foz do Iguaçu, Brazil
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Canine osteoarthritis (OA) is a prevalent disease characterized by progressive joint degeneration, pain, and impaired mobility. In older dogs, OA affects approximately 80% of the population. Current pharmacological treatments are often limited in efficacy and may cause significant adverse effects. In this context, cannabinoids have emerged as a promising therapeutic alternative. This double-blind, randomized study aimed to evaluate the efficacy and safety of a full-spectrum cannabis extract in managing OA-related pain and dysfunction in dogs. Seventeen dogs with OA were randomly assigned to receive either the cannabis extract (containing measured amounts of CBD, THC, CBG, CBC, and other cannabinoids) or a placebo for 90 days. Although the cannabis treatment did not significantly reduce pain levels according to the Helsinki Chronic Pain Index (HCPI) [F(1,14) = 0.001, p = 0.981, η² = 0.000], a reduction of 2.4 points in HCPI scores compared to the placebo was observed at 90 days. Additionally, the treatment proved to be entirely safe, with no significant adverse effects reported. The few mild side effects observed resolved spontaneously within 24 hours. Biomarker analysis revealed no significant differences between the cannabis and placebo groups. Our findings suggest that full-spectrum cannabis extract containing CBD and THC is safe for use in dogs for up to 90 days. However, further research is needed to determine the optimal doses and formulations required to effectively alleviate OA-induced pain.
Keywords: adverse events, Cannabinoids, canine, efficacy, Osteoarthritis, Quality of Life, Safety
Received: 04 Dec 2024; Accepted: 20 Oct 2025.
Copyright: © 2025 Griebeler, Cremonese, Fakih, Pereira, Rial, Leite, Gonçalves, das Almas, Cardoso Júnior, Cezar-dos-Santos, Toci, Mojoli Le Quesne and Nascimento. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Francisney Pinto Nascimento, francisney.nascimento@unila.edu.br
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.